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Purpose: Screening for abdominal aortic aneurysm (AAA) in “men aged over 65 years who 
have ever smoked” is a recommended policy. To reduce the number of screenings, it may be 
of value to define subgroups with a higher prevalence of AAA. Since chronic obstructive pul-
monary disease (COPD) and AAA are associated with several common risk factors, this study 
investigates the prevalence of AAA in COPD patients.
Patients and methods: Patients with COPD were identified via the hospital information sys-
tem. Inclusion criteria were: COPD stage I–IV, ability to give full consent, and age 18 years; 
exclusion criteria were: patient too obese for an ultrasound check, previously diagnosed AAA, 
prior surgery for AAA, or ethical grounds such as concomitant advanced malignant or end-
stage disease. The primary endpoint of the study was an aortic diameter measured by ultrasound 
of 30 mm. Defined secondary endpoints were evaluated on the basis of medical records and 
interviews.
Results: Of the 1,180 identified COPD patients, 589 were included in this prospective study. 
In 22 patients (3.70%), the aortic diameter was 30 mm, representing an AAA prevalence of 
6.72% among males aged 65 years. The risk of AAA increased with the following comorbidi-
ties/risk factors: male sex (odds ratio [OR] 2.98), coronary heart disease (OR 2.81), peripheral 
arterial occlusive disease (OR 2.47), hyperlipoproteinemia (OR 2.77), AAA in the family history 
(OR 3.95), and COPD stage I/II versus IV (OR 1.81).
Conclusion: The overall AAA prevalence of 3.7% in our group of COPD patients is similar 
to that of the general population aged 65 years. However, the frequency of AAA in male 
COPD patients aged 65 years is considerably higher (6.72%) and increased further still in 
those individuals with additional comorbidities/risk factors. Defining subgroups with a higher 
risk of AAA may increase the efficiency of screening.
Keywords: chronic obstructive pulmonary disease, AAA, screening, risk factors, epidemiology, 
inflammatory disease, tobacco abuse
Introduction
In the US,1 the UK,2,3 Denmark,4 and Western Australia,5 recommendations for a 
population-based screening program for abdominal aortic aneurysms (AAA) exist, 
as the general benefits of this approach have been proven.6–10 To date, such programs 
have been realized in the US, England, Sweden, Scotland, Northern Ireland, and 
Norway.11 However, it seems useful to reduce the number of patients to be screened 
by identifying groups at a higher risk of developing AAA. In a previous study, we 
found an elevated AAA prevalence of 8.6% in patients who had been treated for arterial 
disease previously.12 Whether other diseases are also related to AAA remains unclear. 
The US Preventive Services Task Force (USPSTF) defined the criteria for the identi-
fication of persons who should be screened. The main group to screen includes “men 
aged over 65 years who ever smoked”.13,14 It seems meaningful to look for additional 
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conditions that may be associated with a higher prevalence 
of AAA. While a higher prevalence of cardiovascular disease 
in chronic obstructive pulmonary disease (COPD) patients 
has been shown,15 the figures for AAA in COPD patients are 
unclear. Therefore, the objective of the present study is to 
estimate the proportion of hospitalized patients with COPD 
who are also afflicted by AAA.
Patients and methods
We performed a prospective cross-sectional study in our 
hospital. All pulmonary department inpatients with a COPD 
diagnosis were identified via the hospital information sys-
tem. The study was approved by the ethics committee of the 
Charité – Universitätsmedizin Berlin (reg nr EA4/142/13). 
All aspects of the study were in accordance with the Declara-
tion of Helsinki (in its current, revised form). A study nurse 
assessed the identified patients for inclusion and exclusion 
criteria. Inclusion criteria were: COPD stage I–IV,16 mini-
mum age of 18 years, and ability to give full consent. Patients 
too obese for an ultrasound check on technical grounds, 
those with previously diagnosed AAA, and patients who had 
already undergone surgery for AAA were excluded, as were 
some patients on ethical grounds (see “Results”).
If patients met the inclusion criteria, the study nurse 
contacted the responsible physician for further information 
about the patient and his/her circumstances, in order to 
avoid contacting patients in a situation not appropriate for 
discussing a study (eg, concomitant advanced malignant or 
end-stage disease).
Once the treating medical team had established that the 
patient was in an appropriate situation and had agreed to 
the patient being contacted, the patient was informed about 
the study. After obtaining the patient’s oral and written 
consent, the following factors were assessed in a standard-
ized interview: smoking status, hypertension, coronary heart 
disease (CHD), myocardial infarction, peripheral arterial 
occlusive disease (PAOD), stroke, diabetes, hyperlipopro-
teinemia (HLP), pulmonary embolism, thrombosis, hyperu-
ricemia, malignancy, abdominal symptoms, and the family 
history on AAA. Respiratory and other data were extracted 
from the patient’s record.
Ultrasound screening for AAA was performed by a study 
nurse (trained on AortaScan®AMI 9700; Verathon, Bothell, 
WA, USA). AAA was defined as an aortic diameter 30 mm. 
Where an aortic diameter 30 mm was found or in cases of 
ambiguous findings, an angiologist was involved.
Patient characteristics are presented as frequencies and 
percentages for categorical data, and as means with standard 
deviations (SDs) or medians with ranges for continuous 
data. For the analysis, COPD stages I and II were combined. 
Associations between AAA and suspected risk factors were 
evaluated by univariate logistic regression; results are pre-
sented as odds ratios (ORs) with 95% confidence intervals 
(CIs) and P-values, which are considered explorative (with-
out adjusting for multiple testing). Analyses were performed 
in SAS version 9.2 (SAS Institute, Cary, NC, USA).
Results
In a 24-month period (February 2011–February 2013), 
1,481 patients with COPD were identified via the clinical 
information system. Of these, 301 patients were excluded 
because of readmission to the hospital. A total of 1,180 patients 
thus qualified for the study, of whom 589 agreed to participate 
and 591 were excluded. Patients were excluded either because 
they had already received surgery for AAA (13 patients); or on 
ethical grounds, such as concomitant advanced malignant or 
end-stage disease (286 patients); or because they did not agree 
to participate in the study (125 patients). For linguistic reasons, 
29 patients were not able to comply with the requirements for 
giving informed consent and 87 patients had left the hospital 
prior to being contacted. In 51 patients, obesity rendered an 
ultrasound check technically impossible (Figure 1).
The study participants were Caucasian, had a mean age of 
approximately 70 years (only eight patients below 50 years), 
a mean body mass index (BMI) of 25.4 kg/m2, and 54.2% 
were males. The average tobacco consumption was 
50.2 pack-years. C-reactive protein (CRP) was elevated on 
average (26.8 mg/L; normal value 5 mg/L). More than half 
(56%) of the patients were COPD stage IV, with mean forced 
expiratory volume in 1 second (FEV
1
) values of FEV
1
 0.9 L 
and FEV
1 
predicted (pred) 36.8%; maximum vital capacity 
(VC
max
) values of VC
max
 2.0l and VC
max 





 43.2% (Table 1).
Table 2 shows the frequency of comorbidities and poten-
tial confounding factors in these COPD patients. Patients 
were predominately current or former smokers (n=546, 
92.9%) and had additional comorbidities, such as hyperten-
sion (n=369, 63.1%), CHD (n=139, 23.7%), myocardial 
infarction (n=78, 13.3%), PAOD (n=65, 11.1%), and stroke 
(n=44, 7.5%). At least one kind of arterial disease was suf-
fered by 210 patients (35.7%). Overall, 109 patients (18.6%) 
had one arterial disease, 87 patients (14.8%) had two, 
13 patients (2.2%) had three, and one patient (0.2%) suffered 
from four arterial diseases.
In terms of other comorbidities, 141 patients (24%) had 
diabetes, 59 (10%) had HLP, and 127 patients (22%) had 
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malignancies, of which 91 (72%) were in the lower respira-
tory tract (mainly lung cancer). Abdominal symptoms were 
experienced by 43 patients (7.3%), and 16 (2.7%) knew of 
AAA in their families (Table 2).
Among the 589 patients, 22 (3.7%) had an AAA (aortic 
diameter 30 mm; Table 3). Of these 22 patients, 17 (77.0%) 
were males, 20 (91.0%) were current or former smokers, 14 
(63.0%) had hypertension, ten (42.0%) suffered from CHD, 
four (18.0%) had already had a myocardial infarction, five 
(23.0%) suffered from PAOD, three (13.6%) had experi-
enced a stroke, four (18.0%) had diabetes, five (23.0%) had 
HLP, and eight (36.4%) had a malignancy. AAA diameters 
are summarized in Table 4; in most cases, the diameter was 
between 30 mm and 45 mm. The prevalence of AAA was 
5.3% among males and only 1.9% among females. The preva-
lence rates of AAA among patients aged 65 years were 
6.72% and 2.54% for males and females, respectively.
Of all patients with malignancies, 6.3% were afflicted 
by AAA. In the case of AAA in the family history, 9.0% of 
patients had an AAA themselves. Individuals with HLP had 
an AAA in 8.5% of cases, but only 2.8% of patients with 
diabetes had an AAA. Of patients with PAOD, 5.3% were 
Table 1 Basic characteristics and pulmonary function

























Abbreviations: sD, standard deviation; BMI, body mass index; CrP, C-reactive 
protein; COPD, chronic obstructive pulmonary disease; FeV1, forced expiratory 
volume in 1 second; pred, predicted; VC, vital capacity; max, maximum.
Figure 1 Study population flowchart.



















identified as carrying an AAA, as were 6.1% of CHD patients, 
2.8% of patients with a previous myocardial infarction, and 
6.8% of patients with a previous stroke. Of the patients com-
plaining of abdominal symptoms, only 2.5% had an AAA. 
The proportion of patients with thrombosis, pulmonary embo-
lism, hypertension, or current or former tobacco consump-
tion with AAA in this subgroup ranged between 3.4% and 
3.8%, and thus did not differ from the overall median values. 
COPD in stage I or II was associated with AAA in 4.5% of 
cases, COPD in stage III in 4.2%, and COPD in stage IV 
was associated with AAA in 2.5% of patients.
In addition, we looked for further patient data and 
parameters in the patient’s history that might possibly be 
associated with a higher prevalence of AAA. Besides age 
(OR 1.08 per year, P-value 0.004, 95% CI 1.03–1.14) and 
male sex (OR 3.0, P-value 0.034, 95% CI 1.1–8.2), which 
were associated with a higher prevalence of AAA; further 
significant associations were found between CHD (OR 2.8, 
P-value 0.019, 95% CI 1.2–6.7) and the presence of any 
arterial disease (OR 2.7, P-value 0.025, 95% CI 1.13–6.42) 
and AAA. The presence of PAOD alone (OR 2.47, P-value 
0.086, 95% CI 0.88–6.94) or HLP (OR 2.8, P-value 0.054, 
95% CI 0.98–7.81) also showed an increased risk; however, 
these effects did not reach statistical significance. Factors 
tested but not significantly associated with AAA were: BMI 
(OR 1.02, P-value 0.468, 95% CI 0.96–1.09), cigarette pack-
years (OR 1.00, P-value 0.580, 95% CI 0.99–1.01), and CRP 
(OR 1.00, P-value 0.166, 95% CI 1.00–1.01; Figure 2).
Discussion
This prospective study of 589 COPD patients showed 
a prevalence of 3.7% for AAA defined as an aortic 
diameter 30 mm. This prevalence of AAA among COPD 
patients is similar to that seen in screening studies of the gen-
eral population, ie, those not limited to COPD patients (eg, 
the multicenter aneurysm screening study [MASS] 4.9%,3 
Lindholt et al 4.0%3,4). If the calculation is based on the same 
criterion as in the quoted general screening studies – ie, men 
aged 65 years – the prevalence of 6.72% is considerably 
higher and very close to the rate of 6.5% recently cited by 
Divo et al in an overview on COPD comorbidities.17,18 There-
fore, an amendment to the US recommendations for AAA 
screening would generate a higher prevalence of AAA if 
COPD patients were to be defined as a subgroup among “men 
aged 65 years who have ever smoked” who are particu-
larly worth screening. In addition, some other subgroups of 
COPD patients with an even higher prevalence of AAA were 
identified (CHD, HLP, malignoma, positive family history 
for AAA). This is in accordance with the literature, where 
various studies showing, eg, a CHD-related prevalence of 
AAA ranging from 9.0%–14.4% were found.19–22 A highly 
significant risk factor was sex. To be a male with COPD 
means having a three-fold higher risk of developing an AAA. 







Coronary heart disease 139 23.7
Myocardial infarction 78 13.3
Peripheral arterial occlusive disease 65 11.1
stroke 44 7.5
all kinds of arterial diseases 210 35.7
Diabetes mellitus 141 24.1
hyperlipoproteinemia 59 10.1
Pulmonary embolism 26 4.4
Deep vein thrombosis 27 4.6
hyperuricemia 3 0.5
abdominal pain 43 7.3
Malignancy 127 21.6
Malignancies of the lower respiratory tract 91 15.4
Family history of abdominal aortic aneurysm 16 2.7
Table 3 Comorbidities of patients with aaa (30 mm; n=22)
Comorbidity n %
Male 17 77
Current or former smoker 20 91
hypertension 14 63
Coronary heart disease 10 42
Myocardial infarction 4 18





Abbreviation: aaa, abdominal aortic aneurysm.
Table 4 Diameter of identified AAA (30 mm)










Abbreviation: aaa, abdominal aortic aneurysm.
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In contrast to the situation in males, a Cochrane Review for 
screening in women found that 3–5 years after screening, 
women had an OR 1.99 (95% CI 0.36–10.88; versus men 
OR 0.60, 95% CI 0.47–0.78) as compared to an unscreened 
population. This means that more women died in the screened 
population, thus the frequency of ruptured AAA could not be 
reduced by screening in women.23 The same result was found 
by Scott et al.24 The results of a recent Swedish study suggest 
screening subgroups, such as women older than 70 years who 
have ever smoked.25 It thus seems more relevant to develop 
a screening program that includes more risk factors than just 
age, sex, and one major disease like COPD. The combination 
of the above-mentioned risk factors might help to develop 
screening strategies that substantially reduce the number of 
necessary screenings.
In addition to the 22 patients in our study in whom AAA 
was detected, 13 (3.73%) of the 591 excluded patients had 
received prior surgery for AAA, suggesting that within the 
group of excluded patients, AAAs are also present. Of the 
22 patients with an aortic diameter 30 mm, six (27.0%) 
had passed the limit of an AAA diameter of 50 mm at which 
therapeutic options have to be considered. An urgent indica-
tion for considering therapy was detected in four patients.
The observed comorbidities are typical for a population 
with a high prevalence of smokers or ex-smokers with a 
relatively high average of 50.2 pack-years. The nicotine load 
was so high in this population that no difference could be 
observed for AAA patients. Overall, 65 patients (11.0%) were 
already afflicted by PAOD, which shows the importance of 
also screening COPD patients for this disease, as well as for 
other vascular diseases like CHD (23.7%). These anamnes-
tic hints agree with reports in the literature about a higher 
prevalence of AAA in patients with CHD19–22 or noncardiac 
arterial disease.12,26
The Lung Health Study has shown a close relationship 
between COPD and an increased risk of cardiovascular dis-
ease and death.27 This was confirmed by a recently published 
investigation in which 65% of men and 55% of women with 
COPD were afflicted by cardiovascular disease. In the latter 
study, cardiovascular diseases (all grouped together, ie, not 
separated into subgroups) were not a factor contributing to the 
reduction in COPD patients’ health-related quality of life.28 
Inflammation seems to play a major common role in COPD 
and atherosclerosis.29 A study on the association of aortic 
aneurysms and reduced lung function with risk factors such 
as cigarette smoking, cardiovascular disease, and increased 
inflammatory and hemostatic activity found that individuals 
with AAA had a higher frequency of impaired lung func-
tion and a greater incidence of COPD compared to controls 
without an aneurysm.30 In this study, the markers of activated 
inflammation and hemostasis had the most important effect. 
The main factors for the identification of an activation of 
inflammation and hemostasis were plasmin–antiplasmin 





/forced vital capacity (FVC), and 
peak expiratory flow rate (PEFR) – could be demonstrated in 
aneurysm patients compared to a control group with PAOD, 
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Figure 2 Comorbidities and risk factors in COPD.
Note: COPD patients and the likelihood of finding an AAA expressed as odds ratios.
Abbreviations: ChD, coronary heart disease; PaOD, peripheral arterial occlusive disease; aaa, abdominal aortic aneurysm; COPD, chronic obstructive pulmonary 
disease; CI, confidence interval; vs, versus.





patients were not as strongly related to aneurysm formation 
as these markers of inflammation. The authors hypothesized 
that activation of inflammation and hemostasis in response 
to injury may be an important explanation for the association 
between aneurysm formation and reduced respiratory func-
tion. The higher incidence of COPD in aneurysm patients was 
shown in a Dutch case–control study, where the FEV
1
/FVC 
ratio was reduced in an AAA group versus PAOD patients. 
This was apparent in current, former, and never smokers; the 
largest difference was found for the latter group. The authors 
concluded that the pronounced airway obstruction cannot 
be explained by cigarette smoking alone. They suggest that 
other factors in addition to smoking are responsible for the 
association between COPD and AAA.31 Their analysis of 
the factors underlying development of COPD and AAA is 
in accordance with the results of an earlier study, where the 
largest difference in the FEV
1
/FVC ratio was also found in 
the group of never smokers.32 This association could not be 
assessed in the present study, due to the lack of a sufficiently 
large control group of never smokers.
Smoking is not only a risk factor for AAA, but also for 
CHD. However, the relationship between impaired lung 
function and AAA is tighter than the relationship between 
decreased lung function and CHD.31,32 The question is, 
whether both pathologies are part of a process that Fabbri 
and Rabe call “chronic systemic inflammatory syndrome”,33 
a generalized inflammatory process which they assume is 
responsible for various clinical entities. This inflammation 
could cause COPD in the lung and AAA in the vascular 
system. Inflammatory factors such as IL-6, IL1-β, TNF-α, 
MMP-9, MCP-1, and high-sensitivity CRP are elevated in 
COPD patients,29 these factors are known to be elevated in 
AAA patients as well. Reports that statins, with their anti-
inflammatory activity, might have a beneficial role in COPD 
treatment also fit into this pattern.34,35 Statins are known to 
suppress inflammatory activity in the wall of AAA, although 
it has not yet been proven that AAA growth can be retarded 
by statin medication.36–38
In our cohort, an activated level of inflammation with 
a mean CRP of 26.81 mg/L was found, which would be 
consistent with the hypothesis of general inflammation, but 
is certainly not proof of it. We did not find a statistically 
significant relationship between CRP level and an increased 
risk of AAA.
Our findings cannot contribute to solving the problem 
of whether there is a generalized state of inflammation that 
initiates different clinical diseases or whether one of these 
diseases leads to an inflammation that subsequently causes 
other clinical manifestations. Only the third option, ie, that 
these comorbidities exist independently of each other, seems 
to be excluded by both our findings and other reports in 
the literature revealing strong epidemiologic evidence for 
reduced FEV
1
 being a marker for cardiovascular mortality, 
independent of smoking history.39
One limitation of the present study is that out of 1,180 
screened COPD patients, only 589 could be included. There-
fore, selection bias might be present and may have resulted 
in a deviation from the “true” prevalence of AAA in this 
population. However, in half of the excluded patients, the 
grounds for their noninclusion were ethical. Because these 
patients are unlikely to be screened in a real-life setting, this 
patient selection should not lower the practical importance 
of our findings. A further limitation could be the inclusion of 
hospital inpatients only, who might have more severe comor-
bidities than outpatients with COPD. The current study group 
contained twice as many COPD patients with diabetes, almost 
four-times as many patients with CHD, and approximately 
12-times as many individuals with malignancies as COPD 
patients observed by general practitioners.15
Conclusion
The prevalence of AAA in a group of hospitalized COPD 
patients is similar to that of the general population aged 
over 65 years. However, identifying risk factors such as 
male sex and CHD may significantly increase the efficiency 
of screening for AAA. Other factors, such as HLP, PAOD, 
malignancy, and/or a positive family history for AAA also 
increased the risk for AAA, but failed to reach statistical 
significance.
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